Le Lézard
Classified in: Health
Subject: CCA

VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2023 RESULTS CONFERENCE CALL / WEBCAST


MONTREAL, Jan. 22, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2023 on Monday January 29, 2024 after market close. The Company will host a conference call to discuss those results and highlights on Tuesday January 30, 2024 at 8.30am (ET).

To join the conference call without operator assistance, you may register and enter your phone number at https://emportal.ink/3RSJ3aC to receive an instant automated call back.

You can also dial direct to be entered to the call by an Operator. (Traditional conference call instructions here): 

Conference ID: 

50959607



Date: 

Tuesday, January 30, 2024



Time:

8:30am ET



Dial-in numbers: 

1-888-664-6392 or 416-764-8659



Audio replay numbers:

1-888-390-0541 or 416-764-8677



Replay code:

959607 #

A live audio webcast of the conference call will be available via:

https://app.webinar.net/5z6nmw5MNAw

About Valeo Pharma Inc.

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.

Forward Looking Statements

This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

SOURCE Valeo Pharma Inc.


These press releases may also interest you

at 19:21
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced that the Center for Drug...

at 18:30
Cannabix Technologies Inc. (the "Company or Cannabix") reports that it has entered into an arm's length marketing agreements with the following parties: Effective May 13, 2024, the Company has engaged Financial Buzz Media Networks LLC ("FBMN") for...

at 18:25
It is with great pleasure that we announce the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks...

at 18:03
Kelyniam Global , a maker of custom cranial implants, today announced results for its quarter ended March 31, 2024.  Financial highlights for the three months ended March 31, 2024 and the same period in 2023 include:  Total revenue of $957,447...

at 17:56
American Skin Association (ASA) is thrilled to announce that the SPOTS (Sun Protection Outreach Teaching by Students) program will receive the inaugural 2024 Research Achievement Award in Community Education/Outreach at the 2024 Society for...

at 17:55
Living Classrooms Foundation announces a new tree planting and maintenance project along Fort Avenue, the thoroughfare leading to Fort McHenry National Monument and Historic Shrine, taking place on Saturday, May 18. This initiative, involving...



News published on and distributed by: